$RGEN
REPLIGEN CORP Stock $rgen

$rgen Overview Financials Valuation SEC Filings Company Website

2013 Q2 Form 10-Q Financial Statement

#000119312513323245 Filed on August 07, 2013

Income Statement

Concept	2013 Q2	2012 Q2
Revenue	$17.51M	$15.52M
YoY Change	12.79%	102.82%
Cost Of Revenue	$5.298M	$7.345M
YoY Change	-27.87%	372.96%
Gross Profit	$12.21M	$8.179M
YoY Change	49.3%	34.06%
Gross Profit Margin	69.74%	52.69%
Selling, General & Admin	$3.124M	$3.418M
YoY Change	-8.6%	49.32%
% of Gross Profit	25.58%	41.79%
Research & Development	$2.306M	$2.906M
YoY Change	-20.65%	-17.37%
% of Gross Profit	18.88%	35.53%
Depreciation & Amortization	$690.0K	$880.0K
YoY Change	-21.59%	114.63%
% of Gross Profit	5.65%	10.76%
Operating Expenses	$5.430M	$6.324M
YoY Change	-14.14%	8.92%
Operating Profit	$6.103M	$1.318M
YoY Change	363.05%	-1189.26%
Interest Expense	$12.40K	$27.36K
YoY Change	-54.67%	-72.64%
% of Operating Profit	0.2%	2.08%
Other Income/Expense, Net	-$122.0K	$458.0K
YoY Change	-126.64%
Pretax Income	$6.034M	$1.778M
YoY Change	239.37%	-3332.73%
Income Tax	$1.495M	$208.0K
% Of Pretax Income	24.78%	11.7%
Net Earnings	$4.539M	$1.570M
YoY Change	189.11%	-2954.55%
Net Earnings / Revenue	25.92%	10.11%
Basic Earnings Per Share	$0.14	$0.05
Diluted Earnings Per Share	$0.14	$0.05
COMMON SHARES
Basic Shares Outstanding	31.64M shares	30.85M shares
Diluted Shares Outstanding	32.32M shares	31.15M shares

Balance Sheet

Concept	2013 Q2	2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$58.10M	$28.40M
YoY Change	104.58%	-34.86%
Cash & Equivalents	$37.33M	$15.88M
Short-Term Investments	$20.80M	$12.50M
Other Short-Term Assets	$2.000M	$1.100M
YoY Change	81.82%	57.14%
Inventory	$10.56M	$11.50M
Prepaid Expenses
Receivables	$4.871M	$7.812M
Other Receivables	$5.300M	$3.600M
Total Short-Term Assets	$80.91M	$52.36M
YoY Change	54.54%	0.3%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.838M	$9.868M
YoY Change	-0.31%	393.4%
Goodwill	$994.0K	$994.0K
YoY Change	0.0%
Intangibles	$6.499M	$7.177M
YoY Change	-9.44%
Long-Term Investments	$4.600M	$10.90M
YoY Change	-57.8%	-27.81%
Other Assets	$1.800M	$200.0K
YoY Change	800.0%	0.0%
Total Long-Term Assets	$23.74M	$29.09M
YoY Change	-18.39%	49.95%
TOTAL ASSETS
Total Short-Term Assets	$80.91M	$52.36M
Total Long-Term Assets	$23.74M	$29.09M
Total Assets	$104.7M	$81.45M
YoY Change	28.49%	13.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.481M	$2.585M
YoY Change	-42.7%	187.18%
Accrued Expenses	$8.738M	$7.148M
YoY Change	22.23%	224.92%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$10.22M	$9.733M
YoY Change	4.99%	163.05%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.984M	$2.743M
YoY Change	-27.68%	357.16%
Total Long-Term Liabilities	$1.984M	$2.743M
YoY Change	-27.68%	357.16%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.22M	$9.733M
Total Long-Term Liabilities	$1.984M	$2.743M
Total Liabilities	$12.20M	$12.48M
YoY Change	-2.19%	190.14%
SHAREHOLDERS EQUITY
Retained Earnings	-$98.27M	-$116.5M
YoY Change	-15.65%
Common Stock	$318.1K	$308.5K
YoY Change	3.14%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$92.45M	$68.73M
YoY Change
Total Liabilities & Shareholders Equity	$104.7M	$81.45M
YoY Change	28.49%	13.76%

Cashflow Statement

Concept	2013 Q2	2012 Q2
OPERATING ACTIVITIES
Net Income	$4.539M	$1.570M
YoY Change	189.11%	-2954.55%
Depreciation, Depletion And Amortization	$690.0K	$880.0K
YoY Change	-21.59%	114.63%
Cash From Operating Activities	$8.800M	$2.010M
YoY Change	337.81%	-174.17%
INVESTING ACTIVITIES
Capital Expenditures	-$790.0K	-$350.0K
YoY Change	125.71%	105.88%
Acquisitions
YoY Change
Other Investing Activities	$20.00K	$1.740M
YoY Change	-98.85%	-145.08%
Cash From Investing Activities	-$760.0K	$1.380M
YoY Change	-155.07%	-134.24%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.070M	20.00K
YoY Change	5250.0%
NET CHANGE
Cash From Operating Activities	8.800M	2.010M
Cash From Investing Activities	-760.0K	1.380M
Cash From Financing Activities	1.070M	20.00K
Net Change In Cash	9.110M	3.410M
YoY Change	167.16%	-150.59%
FREE CASH FLOW
Cash From Operating Activities	$8.800M	$2.010M
Capital Expenditures	-$790.0K	-$350.0K
Free Cash Flow	$9.590M	$2.360M
YoY Change	306.36%	-192.91%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	31821399	shares
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.08
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2629490	shares
CY2012Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15880006
CY2013Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31814199	shares
CY2013Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	865636	shares
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.53
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1795588	shares
CY2013Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	829273	shares
CY2013Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2013Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	4.48
CY2013Q2	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1 AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1	23	Investment
CY2013Q2	us-gaap	Share Price SharePrice	8.24
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.31
CY2013Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	40000000	shares
CY2013Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2013Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1694909	shares
CY2013Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31814199	shares
CY2013Q2	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	131494
CY2013Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2013Q2	us-gaap	Liabilities Current LiabilitiesCurrent	10218738
CY2013Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	764853
CY2013Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3031594
CY2013Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	11249880
CY2013Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2207589
CY2013Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	189642369
CY2013Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	8737613
CY2013Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1481125
CY2013Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	161420
CY2013Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	1539150
CY2013Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1983583
CY2013Q2	us-gaap	Stockholders Equity StockholdersEquity	92452210
CY2013Q2	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	1499419
CY2013Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-98273154
CY2013Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	475120
CY2013Q2	us-gaap	Preferred Stock Value PreferredStockValue
CY2013Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8737613
CY2013Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	10000
CY2013Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1107977
CY2013Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1852352
CY2013Q2	us-gaap	Common Stock Value CommonStockValue	318142
CY2013Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	104654531
CY2013Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	151000
CY2013Q2	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	4645288
CY2013Q2	us-gaap	Goodwill Goodwill	994000
CY2013Q2	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	25451613
CY2013Q2	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	20805600
CY2013Q2	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	5313397
CY2013Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	5190360
CY2013Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	200000
CY2013Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	6498990
CY2013Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4870982
CY2013Q2	us-gaap	Inventory Net InventoryNet	10557418
CY2013Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1000000
CY2013Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2331487
CY2013Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	21087567
CY2013Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1000000
CY2013Q2	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	416580
CY2013Q2	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	12909696
CY2013Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4336937
CY2013Q2	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	7201000
CY2013Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	1000000
CY2013Q2	rgen	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	123000
CY2013Q2	rgen	Available For Sale Securities Debt Maturities After One Through Two Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue	4645288
CY2013Q2	rgen	Available For Sale Securities Debt Maturities One Through Two Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesOneThroughTwoYearsAmortizedCost	4646013
CY2013Q2	rgen	Marketable Securities Remaining Maturity MarketableSecuritiesRemainingMaturity	P7M25D
CY2013Q2	rgen	Available For Sale Securities Gross Unrealized Loss Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments	5357
CY2013Q2	rgen	Availableforsale Debt Securities Gross Unrealized Gain Accumulated In Investments AvailableforsaleDebtSecuritiesGrossUnrealizedGainAccumulatedInInvestments	12865
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11167745
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31195041	shares
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.20
CY2013Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9837687
CY2013Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	1000000
CY2013Q2	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	1563606
CY2013Q2	us-gaap	Assets Assets	104654531
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	6388888
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	37331578
CY2013Q2	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	1944341
CY2013Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	3405885
CY2013Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	25451613
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	6689614
CY2013Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	3888994
CY2013Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1000000
CY2013Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	2215407
CY2013Q2	us-gaap	Construction In Progress Gross ConstructionInProgressGross	1043170
CY2013Q2	us-gaap	Available For Sale Securities AvailableForSaleSecurities	25459121
CY2013Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	8351342
CY2013Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1611172
CY2013Q2	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	20813833
CY2013Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	20813833
CY2013Q2	us-gaap	Assets Current AssetsCurrent	80914960
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2315090	shares
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	40000000	shares
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31195041	shares
CY2012Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	98162
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10752228
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1911970
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3634839
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10326840
CY2012Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	692212
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	187051253
CY2012Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	8297990
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2454238
CY2012Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	418800
CY2012Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	2899076
CY2012Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2133339
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	84124596
CY2012Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	1459680
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-105150577
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	599120
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8297990
CY2012Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	10000
CY2012Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1376877
CY2012Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1383100
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	311950
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	97010163
CY2012Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	154000
CY2012Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	9914855
CY2012Q4	us-gaap	Goodwill Goodwill	994000
CY2012Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	20745938
CY2012Q4	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	9130515
CY2012Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	5200271
CY2012Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	200000
CY2012Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	7182012
CY2012Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4158758
CY2012Q4	us-gaap	Inventory Net InventoryNet	11143695
CY2012Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2966900
CY2012Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	20279301
CY2012Q4	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	416580
CY2012Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	12802978
CY2012Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4064317
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9952461
CY2012Q4	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	2557384
CY2012Q4	us-gaap	Assets Assets	97010163
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	29209821
CY2012Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	1937238
CY2012Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	4112478
CY2012Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	338814
CY2012Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	20760050
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32115519	shares
CY2012Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	8565112
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1304887
CY2012Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	10845195
CY2012Q4	us-gaap	Assets Current AssetsCurrent	66209451
CY2012Q4	rgen	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	18300
CY2012Q4	rgen	Available For Sale Securities Gross Unrealized Loss Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments	1367
CY2012Q4	rgen	Availableforsale Debt Securities Gross Unrealized Gain Accumulated In Investments AvailableforsaleDebtSecuritiesGrossUnrealizedGainAccumulatedInInvestments	15479
	dei	Trading Symbol TradingSymbol	RGEN
	dei	Entity Registrant Name EntityRegistrantName	REPLIGEN CORP
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2013-06-30
	dei	Entity Central Index Key EntityCentralIndexKey	0000730272
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	us-gaap	Basis Of Accounting BasisOfAccounting	<div> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>1.</b></font></td> <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Basis of Presentation</b></font></td> </tr> </table> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The consolidated financial statements included herein have been prepared by Repligen Corporation (the “Company,” “Repligen” or “we”) in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”), for Quarterly Reports on Form 10-Q and Article 10 of Regulation S-X and do not include all of the information and footnote disclosures required by U.S. GAAP. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012.</font></p> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">In the opinion of management, the accompanying unaudited consolidated financial statements include all adjustments, consisting of only normal, recurring adjustments necessary for a fair presentation of the financial position, results of operations and cash flows. The results of operations for the interim periods presented are not necessarily indicative of results to be expected for the entire year.</font></p> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></p> </div>
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.22
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y1M21D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	388052	shares
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.21
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.86
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	672255	shares
	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P8Y
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	786254	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.84
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	12390684
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y26D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	4.28
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	-18587
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	540552	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.28
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y4D
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31443264	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	121300	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y4M10D
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1105217
	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	762000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-6621
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	695795
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-3817118
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	18088695
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	24947879
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-93182
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1147117
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	9655771
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1140496
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	814837
	us-gaap	Investment Income Net InvestmentIncomeNet	127124
	us-gaap	Revenues Revenues	33964960
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	334937
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
	rgen	Royalty Payment Rate RoyaltyPaymentRate	0.15	pure
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	469000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	562762
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	1341339
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5810909
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4489736
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	5730306
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	18587
	us-gaap	Operating Income Loss OperatingIncomeLoss	9647762
	us-gaap	Royalty Revenue RoyaltyRevenue	9017081
	us-gaap	Net Income Loss NetIncomeLoss	6877423
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-360872
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-1147117
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	12194417
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	992856
	us-gaap	Costs And Expenses CostsAndExpenses	24317198
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2034545
	us-gaap	Share Based Compensation ShareBasedCompensation	562762
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1508943
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	8121757
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	13383003
	us-gaap	Direct Operating Cost Royalty Expense DirectOperatingCostRoyaltyExpense	1219593
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6432039
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2778348
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-492563
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	592030
	us-gaap	Interest Expense InterestExpense	25933
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-958014
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-194945
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2034545
	rgen	Change In Fair Value Of Acquisition Related Contingent Consideration ChangeInFairValueOfAcquisitionRelatedContingentConsideration	-18587
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.09
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.09
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31072445	shares
CY2012Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	458298
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	285046	shares
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0872	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.62
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	3738823
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1539300	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30787399	shares
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	513515
	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	686000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1969
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	502180
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	372715
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	22977047
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	21001840
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	567559
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	3063572
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-643273
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5141897
	us-gaap	Investment Income Net InvestmentIncomeNet	60940
	us-gaap	Revenues Revenues	28348281
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-238285
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	2155131
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-62132
	us-gaap	Operating Income Loss OperatingIncomeLoss	2484814
	us-gaap	Business Combination Bargain Purchase Gain Recognized Amount BusinessCombinationBargainPurchaseGainRecognizedAmount	314244
	us-gaap	Royalty Revenue RoyaltyRevenue	7346441
	us-gaap	Net Income Loss NetIncomeLoss	2796435
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1658864
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	12617800
	us-gaap	Costs And Expenses CostsAndExpenses	25863467
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	134986
	us-gaap	Share Based Compensation ShareBasedCompensation	455669
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1696885
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	4712261
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	24483333
	us-gaap	Direct Operating Cost Royalty Expense DirectOperatingCostRoyaltyExpense	999021
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6846769
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	267137
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-154319
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1239381
	us-gaap	Interest Expense InterestExpense	49741
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1207265
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	212763
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	134986
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	455669
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	992771
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5714121
CY2012	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P8Y
CY2013Q1	us-gaap	Income Tax Expense Benefit Extraordinary Items IncomeTaxExpenseBenefitExtraordinaryItems	298000
CY2012Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.05
CY2012Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.05
CY2012Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	11659239
CY2012Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31149090	shares
CY2012Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	303953	shares
CY2012Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0872	pure
CY2012Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1451500	shares
CY2012Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30845137	shares
CY2012Q2	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	285000
CY2012Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-6130
CY2013Q2	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	142000
CY2013Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-4638
CY2013Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	13013610
CY2013Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-122263
CY2013Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	3650661
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	6102763
CY2013Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	6033703
CY2013Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-883888
CY2013Q2	us-gaap	Investment Income Net InvestmentIncomeNet	65605
CY2013Q2	us-gaap	Revenues Revenues	17508967
CY2012Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1778193
CY2012Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1722999
CY2012Q2	us-gaap	Investment Income Net InvestmentIncomeNet	29516
CY2012Q2	us-gaap	Revenues Revenues	15523820
CY2012Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-159166
CY2012Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	1317739
CY2012Q2	us-gaap	Royalty Revenue RoyaltyRevenue	3864581
CY2012Q2	us-gaap	Net Income Loss NetIncomeLoss	1569963
CY2012Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	7345257
CY2012Q2	us-gaap	Costs And Expenses CostsAndExpenses	14206081
CY2012Q2	us-gaap	Share Based Compensation ShareBasedCompensation	214797
CY2012Q2	us-gaap	Direct Operating Cost Royalty Expense DirectOperatingCostRoyaltyExpense	536933
CY2012Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3418233
CY2012Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	208230
CY2012Q2	us-gaap	Interest Expense InterestExpense	27360
CY2012Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	214797
CY2012Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2905658
CY2013Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.14
CY2013Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.14
CY2013Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32317156	shares
CY2013Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	673461	shares
CY2013Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	520552	shares
CY2013Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31643695	shares
CY2013Q2	us-gaap	Royalty Revenue RoyaltyRevenue	4495357
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	4539187
CY2013Q2	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Aggregate Losses AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses	5000
CY2013Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	5297809
CY2013Q2	us-gaap	Costs And Expenses CostsAndExpenses	11406204
CY2013Q2	us-gaap	Share Based Compensation ShareBasedCompensation	312691
CY2013Q2	us-gaap	Direct Operating Cost Royalty Expense DirectOperatingCostRoyaltyExpense	642736
CY2013Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3123940
CY2013Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1494516
CY2013Q2	us-gaap	Interest Expense InterestExpense	12402
CY2013Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	312691
CY2013Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2306332
CY2013Q2	rgen	Change In Fair Value Of Acquisition Related Contingent Consideration ChangeInFairValueOfAcquisitionRelatedContingentConsideration	35387
CY2012Q4	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	3021000

Files In Submission

Name	View Source	Status
0001193125-13-323245-index-headers.html	Edgar Link	pending
0001193125-13-323245-index.html	Edgar Link	pending
0001193125-13-323245.txt	Edgar Link	pending
0001193125-13-323245-xbrl.zip	Edgar Link	pending
d545902d10q.htm	Edgar Link	pending
d545902dex311.htm	Edgar Link	pending
d545902dex312.htm	Edgar Link	pending
d545902dex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
R1.htm	Edgar Link	pending
R1.xml	Edgar Link	unprocessable
R10.htm	Edgar Link	pending
R10.xml	Edgar Link	unprocessable
R11.htm	Edgar Link	pending
R11.xml	Edgar Link	unprocessable
R12.htm	Edgar Link	pending
R12.xml	Edgar Link	unprocessable
R13.htm	Edgar Link	pending
R13.xml	Edgar Link	unprocessable
R14.htm	Edgar Link	pending
R14.xml	Edgar Link	unprocessable
R15.htm	Edgar Link	pending
R15.xml	Edgar Link	unprocessable
R16.htm	Edgar Link	pending
R16.xml	Edgar Link	unprocessable
R17.htm	Edgar Link	pending
R17.xml	Edgar Link	unprocessable
R18.htm	Edgar Link	pending
R18.xml	Edgar Link	unprocessable
R19.htm	Edgar Link	pending
R19.xml	Edgar Link	unprocessable
R2.htm	Edgar Link	pending
R2.xml	Edgar Link	unprocessable
R20.htm	Edgar Link	pending
R20.xml	Edgar Link	unprocessable
R21.htm	Edgar Link	pending
R21.xml	Edgar Link	unprocessable
R22.htm	Edgar Link	pending
R22.xml	Edgar Link	unprocessable
R23.htm	Edgar Link	pending
R23.xml	Edgar Link	unprocessable
R24.htm	Edgar Link	pending
R24.xml	Edgar Link	unprocessable
R25.htm	Edgar Link	pending
R25.xml	Edgar Link	unprocessable
R26.htm	Edgar Link	pending
R26.xml	Edgar Link	unprocessable
R27.htm	Edgar Link	pending
R27.xml	Edgar Link	unprocessable
R28.htm	Edgar Link	pending
R28.xml	Edgar Link	unprocessable
R29.htm	Edgar Link	pending
R29.xml	Edgar Link	unprocessable
R3.htm	Edgar Link	pending
R3.xml	Edgar Link	unprocessable
R30.htm	Edgar Link	pending
R30.xml	Edgar Link	unprocessable
R31.htm	Edgar Link	pending
R31.xml	Edgar Link	unprocessable
R32.htm	Edgar Link	pending
R32.xml	Edgar Link	unprocessable
R33.htm	Edgar Link	pending
R33.xml	Edgar Link	unprocessable
R34.htm	Edgar Link	pending
R34.xml	Edgar Link	unprocessable
R35.htm	Edgar Link	pending
R35.xml	Edgar Link	unprocessable
R36.htm	Edgar Link	pending
R36.xml	Edgar Link	unprocessable
R37.htm	Edgar Link	pending
R37.xml	Edgar Link	unprocessable
R38.htm	Edgar Link	pending
R38.xml	Edgar Link	unprocessable
R39.htm	Edgar Link	pending
R39.xml	Edgar Link	unprocessable
R4.htm	Edgar Link	pending
R4.xml	Edgar Link	unprocessable
R40.htm	Edgar Link	pending
R40.xml	Edgar Link	unprocessable
R41.htm	Edgar Link	pending
R41.xml	Edgar Link	unprocessable
R42.htm	Edgar Link	pending
R42.xml	Edgar Link	unprocessable
R43.htm	Edgar Link	pending
R43.xml	Edgar Link	unprocessable
R44.htm	Edgar Link	pending
R44.xml	Edgar Link	unprocessable
R45.htm	Edgar Link	pending
R45.xml	Edgar Link	unprocessable
R46.htm	Edgar Link	pending
R46.xml	Edgar Link	unprocessable
R47.htm	Edgar Link	pending
R47.xml	Edgar Link	unprocessable
R48.htm	Edgar Link	pending
R48.xml	Edgar Link	unprocessable
R49.htm	Edgar Link	pending
R49.xml	Edgar Link	unprocessable
R5.htm	Edgar Link	pending
R5.xml	Edgar Link	unprocessable
R50.htm	Edgar Link	pending
R50.xml	Edgar Link	unprocessable
R6.htm	Edgar Link	pending
R6.xml	Edgar Link	unprocessable
R7.htm	Edgar Link	pending
R7.xml	Edgar Link	unprocessable
R8.htm	Edgar Link	pending
R8.xml	Edgar Link	unprocessable
R9.htm	Edgar Link	pending
R9.xml	Edgar Link	unprocessable
report.css	Edgar Link	pending
rgen-20130630.xml	Edgar Link	completed
rgen-20130630.xsd	Edgar Link	pending
rgen-20130630_cal.xml	Edgar Link	unprocessable
rgen-20130630_def.xml	Edgar Link	unprocessable
rgen-20130630_lab.xml	Edgar Link	unprocessable
rgen-20130630_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RGEN
REPLIGEN CORP Stock $rgen

2013 Q2 Form 10-Q Financial Statement

#000119312513323245 Filed on August 07, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGEN REPLIGEN CORP Stock $rgen

2013 Q2 Form 10-Q Financial Statement

#000119312513323245 Filed on August 07, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGEN
REPLIGEN CORP Stock $rgen